合并症对前列腺癌筛查效果的影响:ERSPC鹿特丹长期结果
基于欧洲随机前列腺癌筛查研究鹿特丹中心数据,评估基线合并症对PSA筛查降低前列腺癌特异性死亡率效果的影响。21年随访显示,55-69岁无合并症男性筛查显著降低转移和前列腺癌死亡风险,而有合并症男性无显著获益;70岁以上男性无论合并症状态均无死亡差异。
要点
- 55-69岁无合并症男性PSA筛查显著降低转移和前列腺癌死亡风险。
- 有合并症男性筛查未显著降低转移或前列腺癌特异性死亡率。
- 70岁以上男性无论合并症状态均未观察到前列腺癌死亡差异。
核心结论
- PSA筛查未降低55岁及以上有合并症男性的转移和前列腺癌特异性死亡率。
- PSA筛查降低了55-69岁无合并症男性的转移和前列腺癌特异性死亡率。
- 70岁及以上男性无论基线合并症状态,筛查均未观察到前列腺癌特异性死亡率差异。
研究设计与样本
- 欧洲随机前列腺癌筛查研究(ERSPC)鹿特丹中心筛查臂与对照组长期随访分析。
- 筛查臂每四年提供一次PSA检测,随机分组时通过自报问卷评估合并症。
- 合并症按Charlson合并症指数定义为无合并症 versus ≥1种合并症。
- 主要分析人群为55-69岁男性,70岁及以上男性单独分析。
- 采用竞争风险模型估算转移和前列腺癌特异性死亡的累积发生率,并计算率比(RR)和绝对风险降低。
主要发现
- 21年随访时,有合并症男性中筛查组与对照组的转移风险(RR 0.87;95%CI 0.64-1.17)和前列腺癌特异性死亡风险(RR 1.09;95%CI 0.76-1.56)无显著差异。
- 无合并症男性中,筛查组转移风险(RR 0.62;95%CI 0.52-0.72)和前列腺癌特异性死亡风险(RR 0.67;95%CI 0.54-0.83)均低于对照组。
- 无合并症男性中前列腺癌特异性死亡的绝对风险降低为每1000人5.4例(95%CI 2.4-8.2)。
- 70岁及以上男性中,无论基线合并症状态,均未观察到前列腺癌特异性死亡差异。
临床怎么用
- 在考虑PSA筛查时,应评估男性基线合并症情况,合并症可能影响筛查净获益。
- 对于55-69岁无合并症男性,PSA筛查可显著降低转移和前列腺癌死亡风险。
- 对于有合并症的55岁及以上男性,PSA筛查未显示显著降低前列腺癌特异性死亡率。
- 对于70岁及以上男性,无论合并症状态,筛查均未显示前列腺癌死亡获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Prostate-specific antigen (PSA)-based prostate cancer (PCa) screening can be improved by individualised, risk-stratified strategies. Comorbidity influences life expectancy, so may affect benefits of screening. We evaluated whether the effect of PSA-screening on PCa-specific mortality (PCSM) differed between men with and without comorbidity at baseline. METHODS: In the screening arm of the European Randomized Study of Screening for PCa Rotterdam, PSA-testing was offered every four years. Comorbidity was assessed at randomisation using a self-reported questionnaire, defined as no versus ≥ 1 according to the Charlson Comorbidity Index. Cumulative incidences for metastases and PCSM, accounting for competing risks, were estimated for both comorbidity strata. Rate ratios (RRs) of screening versus control were estimated, adjusted for age at randomisation, with an interaction-term. Absolute risk reductions were calculated. Main analyses were conducted in men 55-69 years; men ≥ 70 years were analysed separately. RESULTS: At 21 years, among men with comorbidity at baseline the risks of metastases (RR:0.87; 95%CI 0.64-1.17) and PCSM (RR:1.09; 95%CI 0.76-1.56) did not differ significantly between the screening and control arm. Without comorbidity, metastases (RR:0.62; 95%CI 0.52-0.72) and PCSM (RR:0.67; 95%CI 0.54-0.83) were lower in the screening arm than in the control arm. The absolute PCSM risk reduction was 5.4 per 1000 men (95%CI 2.4-8.2). No difference in PCSM was observed among men ≥ 70 years, regardless of comorbidity at baseline. CONCLUSION: PSA-screening did not reduce metastases and PCSM in men ≥ 55 years with comorbidity. In contrast, it did in men 55-69 years without comorbidity. This supports consideration of comorbidities in screening.
引用
- Westerhout SF, Remmers S, Bangma CH, et al. Prostate cancer mortality among men with and without comorbidity: Long-term results from the European randomized study of screening for prostate cancer Rotterdam. Eur J Cancer. 2026. PMID: 41997039. doi:10.1016/j.ejca.2026.116741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。